Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells

Iranian Journal of Pharmaceutical Research

Volumn 10, Issue 2, 2011, Pages 329-337

  Taye, Ashraf ^a   Morawietz, Henning ^b  

^a Minia University   (Egypt)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Aldosterone; Endothelium; NADPH oxidase; Oxidative stress; Spironolactone

Indexed keywords

3 NITROTYROSINE; ALDOSTERONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE;

ARTICLE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PROTEIN EXPRESSION; UPREGULATION;

EID: 79959404155     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y and Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension (2006) 48: 165-171.
2. Leopold JA, Damb A and Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B and Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nature Medicine (2007) 13: 189-197.
3. Xavier FE, Aras-Lopez R, Arroyo-Villa I, Campo LD, Salaices M, Rossoni LV, Ferrer M and Balfagon G. Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br. J. Pharmacol. (2008) 154: 1225-1235.
4. Davies JI, Band M, Morris A and Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia (2004) 47: 1687-1694.
5. Edalati fard M, Khatami SMR, Sadeghian S and Salari far M. Renal artery stenosis in patients with coronary artery disease: the prevalence and risk factors, an angiographic study. Daru (2010) 68:355-364.
6. Skott O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE and Jensen BL. Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacol. Ther. (2006) 111: 495-507.
7. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, Lu L, Bhattacharya SK, Postlethwaite AE and Weber KT. Aldosteronesteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ. Res. (2003) 93: e124-135.
8. Iglarz M, Touyz RM, Viel EC, Amiri F and Schiffrin EL. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am. J. Hypertens. (2004) 17: 597-603.
9. Sanz-Rosa D, Oubina MP, Cediel E, De las Heras N, Aragoncillo P, Balfagon G, Cachofeiro V and Lahera V. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid. Redox Signal (2005) 7: 1294-1301.
10. Rajagopalan S, Duquaine D, King S, Pitt B and Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation (2002) 105: 2212-2216.
11. Griendling KK, Sorescu D and Ushio-Fukai M. NAD(P)H oxidase, role in cardiovascular biology and disease. Circ. Res. (2000) 86: 494-501.
12. Jaulmes A, Sansilvestri-Morel P, Rolland-Valognes G, Bernhardt F, Gaertner R, Lockhart BP, Cordi A, Wierzbicki M, Rupin A and Verbeuren TJ. Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells. Thromb. Res. (2009) 124: 439-446.
13. Ones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ and Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am. J. Physiol. (1996) 271: H1626-1634.
14. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F and Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ. Res. (2000) 87: 26-32.
15. Bayraktutan U, Blayney L and Shah AM. Molecular characterization and localization of the NAD(P) H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler. Thromb. Vase. Biol. (2000) 20: 1903-1911.
16. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. (2004) 4: 181-189.
17. Lambeth JD, Cheng G, Arnold RS and Edens WA. Novel homologs of gp91phox. Trends Biochem. Sci. (2000) 25: 459-461.
18. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD and Vega JD. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation (2002) 105: 1429-1435.
19. Hashikabe Y, Suzuki K, Jojima T, Uchida K and Hattori Y. Aldosterone impairs vascular endothelial cell function. J. Cardiovasc. Pharmacol. (2006) 47: 609-613.
20. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G and Koller A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler. Thromb. Vase. Biol. (2003) 23: 418-424.
21. Stier CT Jr., Chander PN and Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol. Rev. (2002) 10: 97-107.
22. Smirnova IV, Sawamura T and Goligorsky MS. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiency. Am. J. Physiol. Renal Physiol. (2004) 287: F25-32.
23. Didion SP, Ryan MJ, Baumbach GL, Sigmund CD and Faraci FM: Superoxide contributes to vascular dysfunction in mice that express human renin and angiotensinogen. Am. J. Physiol. Heart Circ. Physiol. (2002) 283: H1569-1576.
24. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite, the good, the bad, and ugly. Am. J. Physiol. (1996) 271: C1424-1437.
25. Nedvetsky PI, Sessa WC and Schmidt HH. There's NO binding like NOS binding, protein-protein interactions in NO/cGMP signaling. Proc. Natl. Acad. Sci. USA. (2002) 99: 16510-16512.
26. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC and Diez J. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension (2000) 35: 1055-1061.
27. Carlstrom M, Lai EY, Ma Z, Patzak A, Brown RD and Persson AE. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2009) 296: R72-79.
28. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y and Hirata Y. Aldosterone induce superoxide generation via Rac1 activation in endothelial cells. Endocrinology (2008) 149: 1009-1014.
29. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S and Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation (2004) 109: 2213-2220.
30. Macdonald JE, Kennedy N and Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90:n765-770.
31. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M and Hirata Y. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology (2007) 148: 1688-1696.
32. Landmesser U and Drexler H: Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat. Clin. Pract. Cardiovasc. Med. (2005) 2: 628-638.
33. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M., Kagami S, Kondo S, Kiyomoto H, Shokoji, T and Kimura S. Title???? Hypertension (2004) 43: 841-848.
34. Gryglewski RJ, Grodzinska L, Kostka-Trabka E, Korbut R, Bieroon K, Goszcz A and Slawinski M. Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wien Klin. Wochenschr. (1996) 108: 111-116.
35. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H and Kohno M. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J. Am. Soc. Nephrol. (2005) 16: 2906-2912.
36. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J and Horiuchi M. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler. Thromb. Vase. Biol. (2006) 26: 917-921.
37. Park JB and Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension (2001) 37: 1444-1449.
38. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and Evans RM. The nuclear receptor superfamily, the second decade. Cell (1995) 83: 835-839.
39. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R and Aviram M. J. Cardiovasc. Pharmacol. (2003) 41: 955-963.
40. Christ M, Douwes K, Eisen C, Bechtner G, Theisen K and Wehling M. Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension (1995) 25: 117-123.
41. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, Siwik DA and Sam F. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension (2005) 46: 555-561.
42. Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, Yamada H, Tatsumi T, Nakata T and Matsubara H. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens. Res. (2008) 31: 363-375.